Advertisement

Cytotechnology

, Volume 63, Issue 3, pp 285–293 | Cite as

A fusion protein composed of receptor binding domain of vascular endothelial growth factor-A and constant region fragment of antibody: angiogenesis antagonistic activity

  • Feng-Jen Tseng
  • Yen-Ku Liu
  • Yo-Shong Chung
  • Yu-Ling Lin
  • Chia-Hung Chen
  • Wan-Yi Wang
  • Yu-Cheng Chen
  • Nu-Man Tsai
  • Tian-Lu Cheng
  • Ru-Yu Pan
  • Tsung-Ming Hu
  • Ru-Ping Lee
  • Kuang-Wen LiaoEmail author
Original Research

Abstract

Vascular endothelial growth factor (VEGF) promotes the growth of solid tumor mainly via VEGF receptor-1 and receptor-2, which are expressed preferentially in proliferating endothelial cells. Therefore, a strategy for simultaneous blockage of both VEGF receptors may have a useful therapeutic effect in tumor growth. In this study, we utilized a fusion protein which is composed of receptor binding domain of VEGF-A (RBDV) and the constant region fragment (Fc) of a human immunoglobulin G1 (IgG1), to interfere with the growth of human umbilical vein endothelial cells (HUVECs) via VEGF receptors. The results showed that RBDV-IgG1 Fc was able to bind with both VEGF receptor-1 and receptor-2. In addition, RBDV-IgG1 Fc could decrease VEGF-induced proliferation and tube formation among HUVECs. Moreover, the cytotoxic test showed RBDV-IgG1 Fc could also enhance the cytotoxic activity of human natural killing cells. The data are suggesting that the fusion protein, RBDV-IgG1 Fc, may have potential as an angiogenesis antagonist for future tumor therapy.

Keywords

Vascular endothelial growth factor Receptor binding domain of VEGF-A Immunoglobulin Fusion protein Human umbilical vein endothelial cells 

Notes

Acknowledgments

This study was supported by grants from the National Science Council, Taipei, Taiwan (NSC97-2313-B-009-002, NSC-97-2320-B-040-005-MY3) and in part by the ATU-MOE project. This study was also supported by National Chiao Tung University (VGHUST94-P5-28) and Hualien Armed Forces Hospital.

References

  1. Asano M, Yukita A, Matsumoto T, Kondo S, Suzuki H (1995) Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121. Cancer Res 55:5296–5301Google Scholar
  2. Bae DG, Gho YS, Yoon WH, Chae CB (2000) Arginine-rich anti-vascular endothelial growth factor peptides inhibit tumor growth and metastasis by blocking angiogenesis. J Biol Chem 275:13588–13596CrossRefGoogle Scholar
  3. Binetruy-Tournaire R, Demangel C, Malavaud B, Vassy R, Rouyre S, Kraemer M, Plouet J, Derbin C, Perret G, Mazie JC (2000) Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. EMBO J 19:1525–1533CrossRefGoogle Scholar
  4. Caron PC, Laird W, Co MS, Avdalovic NM, Queen C, Scheinberg DA (1992) Engineered humanized dimeric forms of IgG are more effective antibodies. J Exp Med 176:1191–1195CrossRefGoogle Scholar
  5. Eisenbeis CF, Grainger A, Fischer B, Baiocchi RA, Carrodeguas L, Roychowdhury S, Chen L, Banks AL, Davis T, Young D, Kelbick N, Stephens J, Byrd JC, Grever MR, Caligiuri MA, Porcu P (2004) Combination immunotherapy of B-cell non-Hodgkin’s lymphoma with rituximab and interleukin-2: a preclinical and phase I study. Clin Cancer Res 10:6101–6110CrossRefGoogle Scholar
  6. Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581–611CrossRefGoogle Scholar
  7. Fong GH, Rossant J, Gertsenstein M, Breitman ML (1995) Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376:66–70CrossRefGoogle Scholar
  8. Gerber HP, Dixit V, Ferrara N (1998) Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 273:13313–13316CrossRefGoogle Scholar
  9. Gerber HP, Hillan KJ, Ryan AM, Kowalski J, Keller GA, Rangell L, Wright BD, Radtke F, Aguet M, Ferrara N (1999) VEGF is required for growth and survival in neonatal mice. Development 126:1149–1159Google Scholar
  10. Glennie MJ, van de Winkel JG (2003) Renaissance of cancer therapeutic antibodies. Drug Discov Today 8:503–510CrossRefGoogle Scholar
  11. Gluck WL, Hurst D, Yuen A, Levine AM, Dayton MA, Gockerman JP, Lucas J, Denis-Mize K, Tong B, Navis D, Difrancesco A, Milan S, Wilson SE, Wolin M (2004) Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin’s lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin Cancer Res 10:2253–2264CrossRefGoogle Scholar
  12. Heldin CH (1995) Dimerization of cell surface receptors in signal transduction. Cell 80:213–223CrossRefGoogle Scholar
  13. Hiratsuka S, Kataoka Y, Nakao K, Nakamura K, Morikawa S, Tanaka S, Katsuki M, Maru Y, Shibuya M (2005) Vascular endothelial growth factor A (VEGF-A) is involved in guidance of VEGF receptor-positive cells to the anterior portion of early embryos. Mol Cell Biol 25:355–363CrossRefGoogle Scholar
  14. Holash J, Davis S, Papadopoulos N et al (2002) VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 99:11393–11398CrossRefGoogle Scholar
  15. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J (1990) Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348:555–557CrossRefGoogle Scholar
  16. Ito N, Claesson-Welsh L (1999) Dual effects of heparin on VEGF binding to VEGF receptor-1 and transduction of biological responses. Angiogenesis 3:159–166CrossRefGoogle Scholar
  17. Keyt BA, Nguyen HV, Berleau LT, Duarte CM, Park J, Chen H, Ferrara N (1996) Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis. J Biol Chem 271:5638–5646CrossRefGoogle Scholar
  18. Mesiano S, Ferrara N, Jaffe RB (1998) Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 153:1249–1256CrossRefGoogle Scholar
  19. Moulton KS, Heller E, Konerding MA, Flynn E, Palinski W, Folkman J (1999) Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 99:1726–1732Google Scholar
  20. Muller YA, Li B, Christinger HW, Wells JA, Cunningham BC, de Vos AM (1997) Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. Proc Natl Acad Sci USA 94:7192–7197CrossRefGoogle Scholar
  21. Plate KH, Breier G, Millauer B, Ullrich A, Risau W (1993) Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res 53:5822–5827Google Scholar
  22. Prewett M, Huber J, Li Y, Santiago A, O’Connor W, King K, Overholser J, Hooper A, Pytowski B, Witte L, Bohlen P, Hicklin DJ (1999) Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 59:5209–5218Google Scholar
  23. Ruckman J, Green LS, Beeson J, Waugh S, Gillette WL, Henninger DD, Claesson-Welsh L, Janjic N (1998) 2’-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 273:20556–20567CrossRefGoogle Scholar
  24. Shibusa T, Shijubo N, Abe S (1998) Tumor angiogenesis and vascular endothelial growth factor expression in stage I lung adenocarcinoma. Clin Cancer Res 4:1483–1487Google Scholar
  25. Smith JK, Mamoon NM, Duhe RJ (2004) Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy. Oncol Res 14:175–225Google Scholar
  26. Tseng FJ, Chen YC, Lin YL, Tsai NM, Lee RP, Chung YS, Chen CH, Liu YK, Huang YS, Hwang CH, Lai YK, Liao KW (2010) A fusion protein with the receptor binding domain of vascular endothelial growth factor-A (VEGF-A) is an antagonist of angiogenesis in cancer treatment: Simultaneous blocking of VEGF receptor-1 and 2. Cancer Biol Ther 10:865–873Google Scholar
  27. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH (1994) Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 269:26988–26995Google Scholar
  28. Willett CG, Boucher Y, di Tomaso E et al (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145–147CrossRefGoogle Scholar
  29. Wolff EA, Schreiber GJ, Cosand WL, Raff HV (1993) Monoclonal antibody homodimers: enhanced antitumor activity in nude mice. Cancer Res 53:2560–2565Google Scholar
  30. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK (1996) Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 93:14765–14770CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  • Feng-Jen Tseng
    • 1
    • 2
  • Yen-Ku Liu
    • 3
  • Yo-Shong Chung
    • 4
  • Yu-Ling Lin
    • 3
  • Chia-Hung Chen
    • 3
  • Wan-Yi Wang
    • 4
  • Yu-Cheng Chen
    • 3
  • Nu-Man Tsai
    • 5
  • Tian-Lu Cheng
    • 6
  • Ru-Yu Pan
    • 2
    • 7
  • Tsung-Ming Hu
    • 8
  • Ru-Ping Lee
    • 9
  • Kuang-Wen Liao
    • 4
    Email author
  1. 1.Department of OrthopedicsHualien Armed Forces HospitalHualienTaiwan, ROC
  2. 2.Graduate Institute of Medical ScienceNational Defense Medical CenterTaipeiTaiwan, ROC
  3. 3.Institute of Molecular Medicine and BioengineeringNational Chiao Tung UniversityHsin-ChuTaiwan, ROC
  4. 4.Department of Biological Science and TechnologyNational Chiao Tung UniversityHsin-ChuTaiwan, ROC
  5. 5.School of Medical Laboratory and BiotechnologyChung Shan Medical UniversityTaichungTaiwan, ROC
  6. 6.Department of Biomedical Science and Environmental BiologyKaohsiung Medical UniversityKaohsiungTaiwan, ROC
  7. 7.Department of Orthopedics, Tri-Service General HospitalNational Defense Medical CenterTaipeiTaiwan, ROC
  8. 8.Department of PsychiatryYuli Veterans HospitalHualienTaiwan, ROC
  9. 9.Institute of Nursing and Medical Sciences and Department of PhysiologyTzu Chi UniversityHualienTaiwan, ROC

Personalised recommendations